Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.

Source

MarketWatch

Read full article at MarketWatch

Opens original article in a new tab

Factorial Energy goes public at $1.3bn valuation after SPAC merger

about 1 hour agoRead more →

Bloomberg Markets

Oil Prices Are Wrong, Says JPMorgan’s Jack Caffrey

Jack Caffrey, equity portfolio manager at JPMorgan Asset Management, examines the impact of oil prices on equity markets and what that means for both short-term traders and long-term investors. (Source: Bloomberg)

about 1 hour agoRead more →

Bloomberg Markets

Crop and Fertilizer Markets Wipe Out Iran War Risk Premium

The Iran war risk premium that swept through crop and fertilizer markets is rapidly evaporating as fears of prolonged supply disruptions fade, easing one of the biggest threats to food inflation.

about 1 hour agoRead more →

EconomyDaily Composite

Yahoo Finance

Morning Bid: Buy the chip

about 1 hour agoRead more →

Related Economy Stories

Factorial Energy goes public at $1.3bn valuation after SPAC merger

Oil Prices Are Wrong, Says JPMorgan’s Jack Caffrey

Crop and Fertilizer Markets Wipe Out Iran War Risk Premium

Morning Bid: Buy the chip